MEDIA KIT 2020
PRIX GALIEN USA
NEW YORK CITY, OCTOBER 29, 2020
The Prix Galien Award recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments.

The Prix Galien was created in 1970 in honor of Galien, the father of medical science and modern pharmacology. Worldwide the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

The Prix Galien is more than an award: it is a movement with a mandate to foster, recognize and reward excellence in scientific innovation to improve the state of human health. Building on an unrivaled network of top biomedical scientists including Nobel Laureates in medicine, the Prix Galien manages an independent, cross-functional and geographically diverse program of events and sponsorships to brand “the best of the best” in new medicines and diagnostics.

Our scope is global, and our commitment to progress in medicine is both measurable and concrete. Our members express this through the establishment of productive relationships to build lasting bridges between the commercial research enterprise and local communities engaged in public policy, science, finance, academic research and the media.

In addition to recognizing advances in promising therapies, the Prix Galien’s annual Roy Vagelos Pro Bono Humanum Award for humanitarian achievements (www.galienfoundation.org/index.php/2017/01/31/probono) brings a unique focus to the intersection between science, business and politics. The outcome we seek is guided by the synthesis principle that underpins the conduct of science itself: successful innovation where financing, physical assets, knowledge and skills are combined from many sources to move new ideas quickly “from the bench to the bedside,” on behalf of patients everywhere.

A truly global program present in 15 countries*

Our program includes a review of contributions from a new generation of innovators representing diverse sectors in health. Our mission is to advance cross-cultural contacts and harmonize regulation, internal business processes, new information technologies and public-private partnerships to remove barriers to the commercialization of good medicines and expand across to these benefits to all who need them.

HELPFUL LINKS: www.galienfoundation.org

- Prix Galien USA
- Forum (latest programs, participants, registration and reports)
- Pro Bono Humanum Award
- Med StartUp Award
- Prix Galien Around the Globe
- Prix Galien Hall of Fame

*Summary of past 50 years of Prix Galien awards
2020 : Prix Galien’s 50th Anniversary

Africa Now! Senegal, Africa Selected As Permanent Host for The International Prix Galien Awards Ceremony and Launch of the Prix Galien Africa.

The Prix Galien Golden Jubilee : 2020 is a landmark year celebrating 50 years of progress in recognizing excellence in biopharmaceutical and med tech innovations to improve the human condition.

As a special feature our 50th Golden Jubilee year will honor the “global best of the very best” in: A- Pharmaceutical; B- Biotechnology; C- Orphan and Rare diseases; D- Vaccines; and E- Medical technology products. Eligibility will be drawn from the 250 products awarded the Prix Galien by our 14 member-country chapters since 1970, developed by more than 80 innovative companies, most of whom continue to bring new therapies for today’s patients with unmet medical needs.

The Galien Forum and Prix Galien USA Ceremony will take place on October 29 in New York City at the Alexandria Center for Life Science and Museum of Natural History, respectively. During the Ceremony, we will also announce the short list for the “Awards of the Jubilee” – which will be selected by all past and present Committee members across the globe.

The Golden Jubilee awards will be announced on December 11, 2020 in Dakar in the presence of the President of the Senegalese Republic, H.E. Macky Sall, alongside many African heads of state and ministers of health and/or environment, the WHO Director-General, as well as hundreds of scientists and industry and innovation leaders.

The best locale to pursue our mission is the African continent, whose young population is destined to double to 2.5 billion people by 2050. According to the World Economic Forum, early-stage entrepreneurial activity is nearly 15% higher in Africa than the global average – yet while the continent is today home to 11% of the world’s population, it accounts for a mere 1% of total health spending and carries a crippling 25% of the global disease burden. Taken together, these statistics reveal the progress inherent in what in a few years will be the world’s youngest and potentially most productive population, but whose prospects depend on more investment in health care as the key driver of development.

Our diverse geographic reach is evident with the International Prix Galien Awards, which launched in 1990, and is conducted every two years to highlight the “best of the best” in research that brings dividends to patients across geographies with differing health needs. This desire to make biopharmaceutical and med tech innovation a global endeavor, bringing progress to patients in all corners of the world, will now be a key priority for the Prix Galien community going forward.

Under the sponsorship of the government of Senegal and the WHO Regional Office for Africa, the Prix Galien Africa is our first truly region-wide initiative. It stands as a living tribute to the vision of Foundation co-founder, 1986 Nobel peace laureate Elie Wiesel, who believed in medical innovation not only as an industrial policy asset but as a source of social progress, where private enterprise and public engagement combine to deliver a greater public good – health equity and access for all.

We invite all communities with a commitment to the conduct and promotion of life sciences innovation to contribute to this important work.

* Africa, Belgium, Canada, China, France, Germany, Greece, Italy, Netherlands, Poland, Russia, Spain, Switzerland, United Kingdom and the United States.
Thanks to their gifts to society and their determination to alleviate and cure its woes, the scientists deserve to be ranked among the true friends of the human race.

Elie WIESEL In Memoriam
Honorary Founding President
The Galien Foundation
Peace Nobel Laureate
Boston University
PRIX GALIEN USA
COMMITTEE 2020

Susan DESMOND-HELLMANN, MD, MPh
Committee Chair
Former Chief Executive Officer
Bill & Melinda Gates Foundation

Richard AXEL, MD
Nobel Laureate
Co-director
The Kavli Institute for Brain Science. Columbia University Medical Center

Mary-Claire KING, PhD
American Cancer Society
Professor of Genome Sciences and Medical Genetics
University of Washington

Linda B. BUCK, PhD
Nobel Laureate
Fred Hutchinson Cancer Research Center member, and Professor of Physiology and Biophysics
University of Washington

Robert S. LANGER, ScD
David H. Koch Institute Professor
Massachusetts Institute of Technology

Cato T. LAURENCIN, MD, PhD
University Professor
University of Connecticut

Laurie GLIMCHER, MD
President and CEO
Dana Farber Cancer Institute; Professor of Medicine
Harvard Medical School

Paul A. MARKS, MD
Laboratory Head of Cell Biology
Memorial Sloan Kettering Cancer Center

Joseph GOLDSTEIN, MD
Nobel Laureate
Professor of Molecular Genetics and Internal Medicine
UT, Southwestern Medical Center at Dallas

Michael ROSENBLATT, MD
Chief Medical Officer
Flagship Pioneering

Bengt SAMUELSSON, MD, PhD
Nobel Laureate
Professor
Karolinska Institutet; Former President
Karolinska Institutet; Former Chairman
Nobel Foundation

Marc TESSIER-LAVIGNE, PhD
President
Stanford University

P. Roy VAGELOS, MD
Prix Galien USA Committee Chairman 2012-2017
Retired Chairman and CEO
Merck & Co., Inc.; Chairman of the Board
Regeneron Pharmaceuticals, Inc.

Tachi YAMADA, MD
Venture Partner
Frazier Healthcare Partners

Laurie GLIMCHER, MD
President and CEO
Dana Farber Cancer Institute; Professor of Medicine
Harvard Medical School

Richard AXEL, MD
Nobel Laureate
Co-director
The Kavli Institute for Brain Science. Columbia University Medical Center

Mary-Claire KING, PhD
American Cancer Society
Professor of Genome Sciences and Medical Genetics
University of Washington

Linda B. BUCK, PhD
Nobel Laureate
Fred Hutchinson Cancer Research Center member, and Professor of Physiology and Biophysics
University of Washington

Robert S. LANGER, ScD
David H. Koch Institute Professor
Massachusetts Institute of Technology

Cato T. LAURENCIN, MD, PhD
University Professor
University of Connecticut

Laurie GLIMCHER, MD
President and CEO
Dana Farber Cancer Institute; Professor of Medicine
Harvard Medical School

Paul A. MARKS, MD
Laboratory Head of Cell Biology
Memorial Sloan Kettering Cancer Center

Joseph GOLDSTEIN, MD
Nobel Laureate
Professor of Molecular Genetics and Internal Medicine
UT, Southwestern Medical Center at Dallas

Michael ROSENBLATT, MD
Chief Medical Officer
Flagship Pioneering

Bengt SAMUELSSON, MD, PhD
Nobel Laureate
Professor
Karolinska Institutet; Former President
Karolinska Institutet; Former Chairman
Nobel Foundation

Marc TESSIER-LAVIGNE, PhD
President
Stanford University

P. Roy VAGELOS, MD
Prix Galien USA Committee Chairman 2012-2017
Retired Chairman and CEO
Merck & Co., Inc.; Chairman of the Board
Regeneron Pharmaceuticals, Inc.

Tachi YAMADA, MD
Venture Partner
Frazier Healthcare Partners
The Galien Forum, held every autumn at New York’s Alexandria Center for Life Sciences since 2010, offers a full day of dynamic presentations and spirited discussions with top scientists and industry researchers who offer perspectives on the most significant challenges in the global burden of disease and highlights the latest research and clinical pathways toward diagnosis, treatment, and cure.

Our 700 attendees represent the top executive and thought leadership from academic research, industry, government, the regulatory community, patient organizations, international organizations, and the media. Time and again, Forum participants praise the caliber of the speakers and their fellow attendees, the quality of the panel discussions and presentations, and the recognition of industry’s critical role in creating life-saving innovations.

These events represent peer-to-peer exchange with a public purpose, featuring unique opportunities to connect with a diverse range of people, organizations and interests from professional and scientific groups, academia, governmental organizations and patient associations, non-profit organizations and the media.

Topics Debated at Previous Forums Include:
- Cancer Immunotherapeutics
- The Brain Initiative
- Personalized Medicine’s Impact on Drug R&D and Patient Care
- Improving Efficiency in Drug Development
- What is “Value” and How Can it be Measured and Demonstrated in Therapeutic Innovations?
- U.S. Health Reform
- A New Agenda for Global Health
- The Future of Digital Health and its Impact on Healthcare
- New Mechanisms for Industry-Academia Collaboration
- The Future of Targeted Drug Delivery
- Microbiota in Human Disease
- Autism - The Next Decade
- Untangling the Web of Neurodegeneration
- Precision Medicine: Delivering on the Promise
- Molecular Scissors: What Can We Expect from Gene Editing?
I’d also like to congratulate all the candidates for the 5th Annual Prix Galien Awards Competition, which honors those in the pharmaceutical industry who have developed the technical, scientific and clinical research skills necessary to develop innovative medicines and devices. Your work is invaluable.

Margaret A. Hamburg, M.D.
Commissioner of Food and Drugs
US Food and Drug Administration - 2011

“I know the importance of the Prix Galien which rewards every year therapeutic innovations and research works among the most creative.”

Emmanuel Macron
French President - 2018

“I applaud Prix Galien for recognizing the pioneering spirit of America innovation and research.”

John McCain
American Senator - 2008

“The Prix Galien since 1970 is dedicated to promoting the research and development of the medicine and medicine industries.”

Macky Sall
Senegalese President - 2018

“When Olympic rhymes with Galenic: there is a gold medal that can be won for an extraordinary achievement: this is the Galien Award, the Oscar of pharmaceutical research.”

Walter Sutter
Swiss State Advisor, Director of the Public Economy - 2004

“We recognize the importance of the Prix Galien in promoting drug research, and we salute the excellent work of the Jury.”

Philippe Douste-Blazy
French Minister of Foreign Affairs – 2006

“The Galien Foundation, created to honor and catalyze excellence in scientific innovation, recognizes outstanding achievement with the prestigious Prix Galien Award.”

Bill De Blasio
Mayor of the City of New York - 2015

“I know the importance of the Prix Galien which rewards every year therapeutic innovations and research works among the most creative.”

Jean Chretien
Canadian Prime Minister - 1994

“I applaud Prix Galien for recognizing the pioneering spirit of America innovation and research.”

John McCain
American Senator - 2008

“The Prix Galien since 1970 is dedicated to promoting the research and development of the medicine and medicine industries.”

Macky Sall
Senegalese President - 2018

“When Olympic rhymes with Galenic: there is a gold medal that can be won for an extraordinary achievement: this is the Galien Award, the Oscar of pharmaceutical research.”

Walter Sutter
Swiss State Advisor, Director of the Public Economy - 2004

“We recognize the importance of the Prix Galien in promoting drug research, and we salute the excellent work of the Jury.”

Philippe Douste-Blazy
French Minister of Foreign Affairs – 2006

“The Galien Foundation, created to honor and catalyze excellence in scientific innovation, recognizes outstanding achievement with the prestigious Prix Galien Award.”

Bill De Blasio
Mayor of the City of New York - 2015
“I welcome you to the annual Prix Galien awards for innovative excellence in biomedical products and health technologies. The awards are among the highest honors in science and commerce.”

Jimmy Carter
American President - 2017

“I look forward to the day when we will celebrate an African winner of the Prix Galien.”

Tedros Adhanom Ghebreyesus
Director-General, World Health Organization - 2018

“The Prix Galien is a welcome initiative to stimulate creative research and promote excellence.”

Barack Obama
American President - 2008

“I am particularly grateful to receive this Award.”

Bill Clinton
American President - 2010

“The Prix Galien USA recognizes the important research necessary to develop innovative medicines and devices that have a life-saving impact on individuals and families across the globe.”

Kathleen Sebelius
American Secretary of Health and Human Services - 2011

“The Prix Galien Awards are a true celebration of the years of hard work that are required to produce lifechanging interventions.”

Bill & Melinda Gates - 2018

“It is a pleasure to congratulate all those who promote the Prix Galien and pharmaceutical research: they play a vital role in the fight against disease throughout the world.”

John Major
British Prime Minister - 1996

“Prix Galien recognizes men and women from the pharmaceutical and biomedical industries whose contributions of science have improved and saved countless lives.”

Michael Bloomberg
Mayor of the City of New York - 2010

“Prix Galien is the right event, on the right issue at the right time. I thank the Galien Foundation for bringing us together and for recognizing that a healthier world is a safer world and a more just world.”

BAN Ki-moon
UN Secretary-General - 2010
## BY NUMBER OF MEDALS

**Summary of past 50 years of Prix Galien awards**

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>MEDALS</th>
</tr>
</thead>
<tbody>
<tr>
<td>MERCK&amp;CO</td>
<td>63</td>
</tr>
<tr>
<td>NOVARTIS</td>
<td>56</td>
</tr>
<tr>
<td>ROCHE</td>
<td>49</td>
</tr>
<tr>
<td>GSK</td>
<td>40</td>
</tr>
<tr>
<td>PFIZER</td>
<td>33</td>
</tr>
<tr>
<td>SANOFI</td>
<td>31</td>
</tr>
<tr>
<td>J&amp;J - JANSSEN</td>
<td>29</td>
</tr>
<tr>
<td>BMS</td>
<td>22</td>
</tr>
<tr>
<td>AMGEN</td>
<td>20</td>
</tr>
<tr>
<td>BAYER</td>
<td>14</td>
</tr>
<tr>
<td>BOEHRINGER INGELHEIM</td>
<td>12</td>
</tr>
<tr>
<td>SERVIER</td>
<td>11</td>
</tr>
<tr>
<td>BIOGEN</td>
<td>10</td>
</tr>
<tr>
<td>GILEAD SCIENCES</td>
<td>9</td>
</tr>
<tr>
<td>ABBOTT</td>
<td>7</td>
</tr>
<tr>
<td>ASTRAZENECA</td>
<td>7</td>
</tr>
<tr>
<td>TAKEDA</td>
<td>7</td>
</tr>
<tr>
<td>VERTEX PHARMACEUTICALS</td>
<td>7</td>
</tr>
<tr>
<td>ELI LILLY</td>
<td>5</td>
</tr>
<tr>
<td>MERCK KGAA</td>
<td>5</td>
</tr>
<tr>
<td>CHIESI</td>
<td>4</td>
</tr>
<tr>
<td>LUNDBECK</td>
<td>4</td>
</tr>
<tr>
<td>AAZ-LMB</td>
<td>3</td>
</tr>
<tr>
<td>ACTELION</td>
<td>3</td>
</tr>
<tr>
<td>ALEXION</td>
<td>3</td>
</tr>
<tr>
<td>BOSTON SCIENTIFIC</td>
<td>3</td>
</tr>
<tr>
<td>TEVA</td>
<td>3</td>
</tr>
<tr>
<td>ABBVIE</td>
<td>2</td>
</tr>
<tr>
<td>ALMIRALL</td>
<td>2</td>
</tr>
<tr>
<td>ASTELLAS</td>
<td>2</td>
</tr>
<tr>
<td>CHUGAI PHARMA</td>
<td>2</td>
</tr>
<tr>
<td>CTRS</td>
<td>2</td>
</tr>
<tr>
<td>EDWARDS LIFESCIENTES</td>
<td>2</td>
</tr>
<tr>
<td>FRESENIUS BIOTECH</td>
<td>2</td>
</tr>
<tr>
<td>IPSEN</td>
<td>2</td>
</tr>
<tr>
<td>MEDTRONIC</td>
<td>2</td>
</tr>
<tr>
<td>PIERRE FABRE</td>
<td>2</td>
</tr>
<tr>
<td>PTC THERAPEUTICS</td>
<td>2</td>
</tr>
<tr>
<td>ROEHM-PHARMA</td>
<td>2</td>
</tr>
<tr>
<td>SIEMENS</td>
<td>2</td>
</tr>
<tr>
<td>SYSMEX</td>
<td>2</td>
</tr>
<tr>
<td>AFA CROHN RCH FRANCE</td>
<td>1</td>
</tr>
<tr>
<td>ALBANA PHARMA</td>
<td>1</td>
</tr>
<tr>
<td>ALNLAM NETHERLANDS BV.</td>
<td>1</td>
</tr>
<tr>
<td>AMICUS</td>
<td>1</td>
</tr>
<tr>
<td>ASTA PHARMA</td>
<td>1</td>
</tr>
<tr>
<td>BAXTER</td>
<td>1</td>
</tr>
<tr>
<td>BD</td>
<td>1</td>
</tr>
<tr>
<td>BIOCARTIS</td>
<td>1</td>
</tr>
<tr>
<td>BIOCHEM-PHARMA</td>
<td>1</td>
</tr>
<tr>
<td>BIOCODEX</td>
<td>1</td>
</tr>
<tr>
<td>EDAP TMS</td>
<td>1</td>
</tr>
<tr>
<td>EOS SAS</td>
<td>1</td>
</tr>
<tr>
<td>EXACT SCIENCES</td>
<td>1</td>
</tr>
<tr>
<td>FACULTY OF PHARMA ANGERS</td>
<td>1</td>
</tr>
<tr>
<td>FERRER</td>
<td>1</td>
</tr>
<tr>
<td>FISONS</td>
<td>1</td>
</tr>
<tr>
<td>FROSST</td>
<td>1</td>
</tr>
<tr>
<td>GENERIUM</td>
<td>1</td>
</tr>
<tr>
<td>GUERBE ET</td>
<td>1</td>
</tr>
<tr>
<td>INSIGHTEC</td>
<td>1</td>
</tr>
<tr>
<td>INSTITUT STUCHU</td>
<td>1</td>
</tr>
<tr>
<td>INTERCEPT PHARMACEUTICALS</td>
<td>1</td>
</tr>
<tr>
<td>IONIS PHARMACEUTICALS</td>
<td>1</td>
</tr>
<tr>
<td>LEO</td>
<td>1</td>
</tr>
<tr>
<td>LFB</td>
<td>1</td>
</tr>
<tr>
<td>LIFEINA</td>
<td>1</td>
</tr>
<tr>
<td>MENARINI</td>
<td>1</td>
</tr>
<tr>
<td>NEW YORK BLOOD CENTER</td>
<td>1</td>
</tr>
<tr>
<td>HOWARD MILSTEIN</td>
<td>1</td>
</tr>
<tr>
<td>NORGINE GMBH</td>
<td>1</td>
</tr>
<tr>
<td>PHARMAPHARM</td>
<td>1</td>
</tr>
<tr>
<td>RECORDATI PHARMA</td>
<td>1</td>
</tr>
<tr>
<td>SMITH &amp; NETHEW</td>
<td>1</td>
</tr>
<tr>
<td>SOPHAMEDICA</td>
<td>1</td>
</tr>
<tr>
<td>SPARK THERAPEUTICS</td>
<td>1</td>
</tr>
<tr>
<td>STRYKER</td>
<td>1</td>
</tr>
<tr>
<td>SVR</td>
<td>1</td>
</tr>
<tr>
<td>SWEDISH ORPHAN</td>
<td>1</td>
</tr>
<tr>
<td>INTERNATIONAL</td>
<td>1</td>
</tr>
<tr>
<td>SYADEM - GROUPE D’ETUDES EN PREVENTOLOGIE</td>
<td>1</td>
</tr>
<tr>
<td>T2 BIOSYSTEMS</td>
<td>1</td>
</tr>
<tr>
<td>URGO MEDICAL</td>
<td>1</td>
</tr>
<tr>
<td>VIRON THERAPEUTICS</td>
<td>1</td>
</tr>
<tr>
<td>Updated January 2020</td>
<td></td>
</tr>
</tbody>
</table>

## THE MEDAL

**by Albert De Jaeger**

The Prix Galien medal was designed by Albert de Jaeger [1908 – 1992], laureate of the Premier Grand Prix de Rome architectural prize. De Jaeger designed medals for prominent figures such as Pope Pius XII (at the Villa Medici, 1937) and Pope Jean-Paul I, Presidents Dwight D. Eisenhower and John F. Kennedy, distinguished military leaders including Marshals Leclerc, Koenig, Montgomery, Marshall and Joukov; the Weizmann Institute, as well as numerous artists, literary figures and prominent personalities such as Sacha Guitry, Marcel Proust, Henri de Montherlant, Paul Harris, a number of Nobel Prize laureates, the Empress of Iran SA Farah Diba, Princess Grace of Monaco, and others...

De Jaeger is also the architect of numerous outstanding monuments in France and throughout the world.
Our annual gala awards dinner is a creative recognition of the productive and positive power of partnerships that drive progress in medical science. It is peer exchange with a public purpose - with a diverse range of opportunities for contact with a range of interests, from professional and scientific groups, academia and governments to patient associations, other non-profit organizations and the media.

WHAT PREVIOUS PRIX GALIEN WINNERS HAVE SAID UPON RECEIVING THE HONOUR

“The Galien Foundation brings together the top scientists in the world. You have Nobel Laureates across the spectrum of scientific disciplines meeting and talking with members of the pharmaceutical industry to see what’s going on at the cutting edge, because ultimately that’s going to benefit patients.”

William Hait, MD, PhD
Global Head, Research & Development, Janssen, Pharmaceutical Companies of Johnson & Johnson

“Merck’s mission is to translate science into medically important products that positively impact humanity, so it is natural for us to support the Prix Galien, since it supports exactly that.”

Kenneth C. Frazier
Chairman, CEO and President, Merck

“Our 2016 Prix Galien award highlights not only the breakthrough science behind Cologuard, but also the unrivaled team that worked to develop and bring to market an innovation with the potential to make a significant impact in eradicating colorectal cancer. We are humbled and thankful to be counted among the companies honored by the Galien Foundation.”

Graham Lidgard, PhD
Chief Science Officer, Exact Sciences

“Our 2016 Prix Galien USA awards [for Cosentyx and Gleevec] … represent years of hard work by our scientists. These wins underscore our commitment to addressing the unmet medical needs of patients through science-based innovation.”

Joseph Jimenez, CEO, Novartis

“Our goal — to combine the best science with the most efficient drug development plan and deliver transformational medicines to patients in need — is completely aligned with the Galien Foundation mission to promote innovations that improve the human condition.”

Mace L. Rothenberg, MD
Chief Development Officer, Oncology, Pfizer Global Product Development
The committee follows a century-old example set in Sweden. The Prix Galien rewards excellence and novelty, and awards special honors to those who have served humanity at large. Presented at the Ceremony, the Pro Bono Humanum Award recognizes exemplary and innovative efforts in improving the human condition. This special award was presented by the late and beloved Elie Wiesel, in presence of the Prix Galien USA Committee. The Pro Bono Humanum Award was renamed the Roy Vagelos Pro Bono Humanum Award in 2017 in recognition of his decades of leadership in improving the state of human health through medicines innovation.

2019

**JIM AND MARILYN SIMONS**
The Simons Foundation

In recognition of their proactive support of basic scientific research undertaken in the pursuit of understanding the phenomena of our world, often including research by scientists in the early stages of their careers, a new collaborative funding model to facilitate cross-disciplinary breakthroughs, and efforts to inspire emerging and current philanthropists to dedicate a portion of their philanthropy to basic science.

2018

**BILL AND MELINDA GATES**
Bill & Melinda Gates Foundation

In recognition of their extraordinary work championing scientific and technological innovation to improve life for the world’s poorest people. As co-chairs of the Bill & Melinda Gates Foundation, they have catalyzed unprecedented progress in global health, poverty reduction, and public education in the U.S.

2017

**JIMMY CARTER**
Former U.S. President & Co-Founder, The Carter Center

For playing a leadership role in the elimination of river blindness in four of the six Latin American countries where it was endemic and halting the disease’s transmission in several locations in Africa where more than 99 percent of the global cases exist.

2016

**PAULA S. APSELL**
Executive Producer, PBS NOVA series & Director, Science Unit, WGBH

For turning great science into a human story, showing that scientific literacy is society’s first line of defense against the destructive forces of fear and ignorance that challenge further progress in human health.

2015

**PR. MARY-CLAIRE KING**
Professor, Genome Sciences and Medical Genetics, University of Washington

In recognition of her work in transforming the application of human genetics to medicine through identification of the first gene, BRCA1, responsible for inherited susceptibility to breast cancer. And for pioneering the application of genetic sequencing in forensics to identify victims of human rights abuse.

2014

**DR. BERNARD KOUCHNER**
Co-Founder, Doctors Without Border & Former French Minister of Foreign and European Affairs

In recognition of his role in the creation, from amongst French doctors, this group of “Doctors Without Borders” who have lent the modern field of humanitarian medicine both legitimacy and worldwide acclaim and for his fieldwork that has nurtured and developed, not only among public opinion but also within various governments, the notion of the universality of humanitarian action and the concept of the Non-Governmental Organization.

2013

**DR. ANTHONY FAUCI**
Director, U.S. National Institute of Allergy and Infectious Diseases

For his paramount contributions to basic and clinical research on the pathogenesis and treatment of immune mediated and infectious diseases.

2012

**DR. FRANCIS S. COLLINS**
Director, U.S. National Institutes of Health

Dr. Collins, Director of the National Institutes of Health (N.I.H). In recognition of his contribution to the ethical implications of scientific research.

2011

**PR. PAUL FARMER**
Chief Strategist and Co-Founder, Partners In Health

For his humanitarian work in Haiti and throughout the world, including advancing the fight against infectious diseases, including AIDS and tuberculosis.

2010

**BILL CLINTON AND PHILIPPE DOUSTE-BLAZY**
Founder, Clinton Foundation and Former U.S. President; Chairman, UNITAID

In recognition of their achievements in providing treatment and increasing access to medicines for underserved populations through the UNITAID and Clinton Foundation HIV/AIDS Initiative (CHAI) partnership.
The Prix Galien USA committee, a group of highly accomplished individuals from the scientific and research communities, will judge which among the candidates, independent of any category, is the best pharmaceutical agent (i.e. small molecule), the best biotechnology product and the best medical technology approved by the FDA in the past five years. As few as one or as many as three prizes may be awarded in each of these categories, and the committee may decide on awards hors prix. The prizes are awarded for products and agents that significantly improve the human condition.
The mission of The Prix Galien-MedStartup program is to foster private-sector collaborations to treat and cure medical conditions that pose a threat to public health worldwide and promotes foster innovative research partnerships among major integrated pharmaceutical companies, biotech firms, and medical device manufacturers, producers of vaccines, academic research institutes, and health care organizations, including e-health vendors.

This unique initiative, which takes place in the same venue and at the same time as the Galien Forum, was built on several years of cooperation between the Galien Foundation and Business France with three core goals:

- Strengthen commercial partnerships that bridge the traditional silos between government, industry and academia;
- Defray the growing complexity and cost burden of medicines R&D;
- Promote cross-border trade, jobs, and economic growth.

A focal point of the program is the active participation of the most innovative start-up companies who are seeking US partners to share research and support global commercial development of promising lead technologies.

**Chairman:** Bernard POUSSOT
Director, Roche Holding, Former Chairman & CEO, WYETH

**THE JURY**

**Roch DOLIVEUX**
Honorary CEO, UCB

**Jean-Pierre GARNIER**
Former CEO, GSK

**Penny HEATON**
CEO, Bill & Melinda Gates Medical Research Institute

**Mikael DOLSTEN**
Global R&D President, Pfizer

**François MAISONROUGE**
Senior Managing Director, Evercore Partners

**Franz HUMER**
Former CEO, Roche

**Paul STOFFELS**
Chief Scientific Officer, Johnson and Johnson

**Elias ZERHOUNI**
Global R&D President, Sanofi

**EACH YEAR THE JURY NOMINATES CANDIDATES FOR FOUR AWARDS IN THE FOLLOWING CATEGORIES:**

- Best Collaboration in the Pharmaceutical or Biotechnology industry
- Best Collaboration in the Medtech or Digital Health sector
- Best Collaboration dedicated to the developing or underserved populations worldwide

**JOIN US ON:**
http://medstartup.galienfoundation.org
PRIX GALIEN USA WINNERS

AND IN 2020, THE WINNERS ARE...

2019
• Best Pharmaceutical Product: SHINGRIX, GlaxoSmithKline
• Best Biotechnology Product: LUXTURNATM, Spark Therapeutics
• Best Medical Technology: FreeStyle® Libre 14 Day Flash Glucose Monitoring System, Abbott
• Pro Bono Humanum Award: Jim and Marilyn Simons, The Simons Foundation

2018
• Best Pharmaceutical Product: IDHIFA®, Celgene Agios
• Best Biotechnology Product: Yescarta®, Kite, a Gilead Company & Kymriah®, Novartis Pharmaceuticals Corporation
• Best Medical Technology: WATCHMAN™, Boston Scientific Corporation
• Pro Bono Humanum Award: Bill and Melinda Gates. Co-Chairs, Bill & Melinda Gates Foundation

2017
• Best Pharmaceutical Product: Venclexta™, AbbVie & Genentech (a Member of the Roche Group)
• Best Biotechnology Product: SPINRAZA®, Biogen & Ionis Pharmaceuticals
• Best Medical Technology: Exablate Neuro, INSIGHTEC
• Pro Bono Humanum Award: Former President Jimmy Carter

2016
• Best Pharmaceutical Agent: Ibrance®, Pfizer, Inc.
• Best Biotechnology Product: Cosentyx®, Novartis
• Best Medical Technology: Cologuard®, Exact Sciences

2015
• Best Pharmaceutical Agent: IMBRUVICA®, Janssen Biotech, Inc. & Pharmacyclics LLC, an AbbVie Company
• Best Biotechnology Product: OPDIVO®, Bristol-Myers Squibb KEYTRUDA®, Merck & Co., Inc.
• Best Medical Technology: T2Candida Panel, T2 Biosystems, Inc.
• Pro Bono Humanum Award: Dr. Anthony S. Fauci

2014
• Best Pharmaceutical Agent: Sovaldi® - Gilead Sciences
• Best Biotechnology Product: HEMACORD® - The New York Blood Center’s Howard P. Milstein Cord Blood Center
• Best Medical Technology: Trevo ProVue® - Stryker
• Pro Bono Humanum Award: Dr. Bernard Kouchner

2013
• Best Pharmaceutical Agents: Zelboraf® - Genentech
• Best Biotechnology Product: Zostavax® - Merck & Co., Inc.
• Best Medical Technology product: S-ICD® System - Boston Scientific
• Pro Bono Humanum Award: Dr. Anthony S. Fauci

2012
• Best Pharmaceutical Agents: Vicitrelis® - Merck & Co., Inc.; Incivek® - Vertex Pharmaceuticals
• Best Biotechnology Product: Yervoy® - Bristol-Myers Squibb
• Best Medical Technology product: Sapien® - Edwards Lifesciences Melody® - Medtronic
• Pro Bono Humanum Award: Dr. Francis S. Collins

2011
• Best Pharmaceutical Agent: Prevnar13® - Novartis
• Best Biotechnology Product: Stelara® - Janssen Prolia and XGEVA® - Amgen
• Pro Bono Humanum Award: Paul Farmer

2010
• Best Pharmaceutical Agent: Coartem® - Novartis
• Best Biotechnology Product: RotaTeq® - Merck & Co., Inc.
• Best Medical Technology: xTAG® - Lumexin Corporation
• Pro Bono Humanum Award: Bill Clinton and Philippe Douste-Blazy

2009
• Best Pharmaceutical Agent: Gleevec® - Novartis
• Best Biotechnology Product: Nplate® - Amgen; Promacta® - GlaxoSmithKline
• Best Medical Technology: Cellsearch® - Veridex [J&J]
• Pro Bono Humanum Award: Jeffrey Sachs and Barry Bloom

2008
• Best Pharmaceutical Agent: Isentress® - Merck & Co., Inc.; Selzentry® - Pfizer
• Best Biotechnology Product: Soliris® - Alexion; Infuse® - Wyeth
• Special therapeutic development: Revlimid® - Celgene
• Pro Bono Humanum Award: Sheldon Segal

2007
• Best Pharmaceutical Agent: Januvia® - Merck & Co., Inc.; Chantix® - Pfizer
• Best Biotechnology Product: Humira® - Abbott; Gardasil® - Merck & Co., Inc.
• Pro Bono Humanum Award: Dr. Roy Vagelos

2006
• Best Pharmaceutical Product: Venclexta™, AbbVie & Genentech (a Member of the Roche Group)
• Best Biotechnology Product: SPINRAZA®, Biogen & Ionis Pharmaceuticals
• Best Medical Technology: Exablate Neuro, INSIGHTEC
• Pro Bono Humanum Award: Former President Jimmy Carter

2005
• Best Pharmaceutical Agent: Sovaldi® - Gilead Sciences
• Best Biotechnology Product: HEMACORD® - The New York Blood Center’s Howard P. Milstein Cord Blood Center
• Best Medical Technology: Trevo ProVue® - Stryker
• Pro Bono Humanum Award: Dr. Bernard Kouchner

2004
• Best Pharmaceutical Agents: Zelboraf® - Genentech
• Best Biotechnology Product: Zostavax® - Merck & Co., Inc.
• Best Medical Technology product: S-ICD® System - Boston Scientific
• Pro Bono Humanum Award: Dr. Anthony S. Fauci

2003
• Best Pharmaceutical Agent: IMBRUVICA®, Janssen Biotech, Inc. & Pharmacyclics LLC, an AbbVie Company
• Best Biotechnology Product: OPDIVO®, Bristol-Myers Squibb KEYTRUDA®, Merck & Co., Inc.
• Best Medical Technology: T2Candida Panel, T2 Biosystems, Inc.
• Pro Bono Humanum Award: Dr. Francis S. Collins

2002
• Best Pharmaceutical Agent: Prevnar13® - Novartis
• Best Biotechnology Product: Stelara® - Janssen Prolia and XGEVA® - Amgen
• Pro Bono Humanum Award: Paul Farmer

2001
• Best Pharmaceutical Agent: Coartem® - Novartis
• Best Biotechnology Product: RotaTeq® - Merck & Co., Inc.
• Best Medical Technology: xTAG® - Lumexin Corporation
• Pro Bono Humanum Award: Bill Clinton and Philippe Douste-Blazy

2000
• Best Pharmaceutical Agent: Gleevec® - Novartis
• Best Biotechnology Product: Nplate® - Amgen; Promacta® - GlaxoSmithKline
• Best Medical Technology: Cellsearch® - Veridex [J&J]
• Pro Bono Humanum Award: Jeffrey Sachs and Barry Bloom

1999
• Best Pharmaceutical Agent: Isentress® - Merck & Co., Inc.; Selzentry® - Pfizer
• Best Biotechnology Product: Soliris® - Alexion; Infuse® - Wyeth
• Special therapeutic development: Revlimid® - Celgene
• Pro Bono Humanum Award: Sheldon Segal

1998
• Best Pharmaceutical Agent: Januvia® - Merck & Co., Inc.; Chantix® - Pfizer
• Best Biotechnology Product: Humira® - Abbott; Gardasil® - Merck & Co., Inc.
• Pro Bono Humanum Award: Dr. Roy Vagelos

1997
• Best Pharmaceutical Product: Venclexta™, AbbVie & Genentech (a Member of the Roche Group)
• Best Biotechnology Product: SPINRAZA®, Biogen & Ionis Pharmaceuticals
• Best Medical Technology: Exablate Neuro, INSIGHTEC
• Pro Bono Humanum Award: Former President Jimmy Carter

1996
• Best Pharmaceutical Agent: Sovaldi® - Gilead Sciences
• Best Biotechnology Product: HEMACORD® - The New York Blood Center’s Howard P. Milstein Cord Blood Center
• Best Medical Technology: Trevo ProVue® - Stryker
• Pro Bono Humanum Award: Dr. Bernard Kouchner

1995
• Best Pharmaceutical Agents: Zelboraf® - Genentech
• Best Biotechnology Product: Zostavax® - Merck & Co., Inc.
• Best Medical Technology product: S-ICD® System - Boston Scientific
• Pro Bono Humanum Award: Dr. Anthony S. Fauci

1994
• Best Pharmaceutical Agent: IMBRUVICA®, Janssen Biotech, Inc. & Pharmacyclics LLC, an AbbVie Company
• Best Biotechnology Product: OPDIVO®, Bristol-Myers Squibb KEYTRUDA®, Merck & Co., Inc.
• Best Medical Technology: T2Candida Panel, T2 Biosystems, Inc.
• Pro Bono Humanum Award: Dr. Anthony S. Fauci

1993
• Best Pharmaceutical Agent: Prevnar13® - Novartis
• Best Biotechnology Product: Stelara® - Janssen Prolia and XGEVA® - Amgen
• Pro Bono Humanum Award: Paul Farmer

1992
• Best Pharmaceutical Agent: Coartem® - Novartis
• Best Biotechnology Product: RotaTeq® - Merck & Co., Inc.
• Best Medical Technology: xTAG® - Lumexin Corporation
• Pro Bono Humanum Award: Bill Clinton and Philippe Douste-Blazy

1991
• Best Pharmaceutical Agent: Gleevec® - Novartis
• Best Biotechnology Product: Nplate® - Amgen; Promacta® - GlaxoSmithKline
• Best Medical Technology: Cellsearch® - Veridex [J&J]
• Pro Bono Humanum Award: Jeffrey Sachs and Barry Bloom

1990
• Best Pharmaceutical Agent: Isentress® - Merck & Co., Inc.; Selzentry® - Pfizer
• Best Biotechnology Product: Soliris® - Alexion; Infuse® - Wyeth
• Special therapeutic development: Revlimid® - Celgene
• Pro Bono Humanum Award: Sheldon Segal

1989
• Best Pharmaceutical Agent: Januvia® - Merck & Co., Inc.; Chantix® - Pfizer
• Best Biotechnology Product: Humira® - Abbott; Gardasil® - Merck & Co., Inc.
• Pro Bono Humanum Award: Dr. Roy Vagelos
AND THE 2020 WINNER IS?

ACTORS WIN OSCARS...

INNOVATORS WIN PRIX GALIEN USA

The Prix Galien Award recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments.

The Prix Galien was created in 1970 in honor of Galien, the father of medical science and modern pharmacology.

Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

The Prix Galien Foundations
99 John Street, Suite 2502 / New York, NY 10038
Tel: 212-685-1592

www.galienfoundation.org